Recall Alert: SUBSTANDARD PRODUCTS DECLARED BY PROVINCIAL DRUG TESTING LABORATORIES.

Recall Alert

DRAP Alert NoNo I/S/04-25-35
Action Date07th April, 2025.
Target Audience– National Regulatory Field Force.
– Pharmacists and Chemists
in Distribution, Pharmacies and Medical Stores
– Healthcare Professionals – Physicians, Pharmacists, and Nurses at hospitals and clinics
– General Public
Problem / Issue Directorate of Drug Control (DDC) Punjab has informed Drug Regulatory Authority of Pakistan that the samples of below mentioned products have been reported as ‘Substandard’.

Therapeutic Goods (s) Affected: –

Product NamesCompositionBatch DetailsManufactured byTest Results
Amekoran Injection

 
Reg. No. 053627
Each 2mL contains:
Amikacin (as Sulphate).…250mg
BK-019M/s Ameer Pharma (Pvt) Ltd,
23-Km, Sheikhupura Road, Lahore.
‘Substandard’ on the basis of visible particulates.
Ortizin Tablet

 
Reg. No. 025405
Each film coated tablet contains:
Cetirizine dihydrochloride.…10mg
24I268M/s. Obsons Pharmaceuticals,
209-S, Quaid-e-Azam Industrial Estate, Kot Lakhpat, Lahore.
‘Substandard’ with regards to impurities.
AQUA-P Injection

 
Reg. No. 034290
Sterile water for Injection 5mlP-669M/s. IPRAM International,
Plot No. 26, St # S.S-3, National Industrial Zone,  Rawat.
‘Substandard’ on the basis of visible particulate matter. 
Injection Dorcip 100ml


Reg. No. 046086
Ciprofloxacin as lactate….2mg/mlDC-121M/s. Trigon Pharmaceuticals (Pvt) Ltd. 8-Km, Thokar Raiwind Road, Lahore.  ‘Substandard’ with regards to visible particulates in injection and Sterility Test.
Meclomine Tablet 500mcg

Reg. No.  042601
Each film coated tablet contains:
Mecobalamine…500mcg
8482M/s Alfalah Pharma (PVT) Ltd.,
12-Km, Sheikhupura Road, Lahore.
‘Adulterated’ as per section 3(a)(iv) of Drugs Act, 1976.
Meclomine Tablet 500mcg


Reg. No. 042601
Each film coated tablet contains:
Mecobalamine…500mcg
8440M/s Alfalah Pharma (PVT) Ltd.,
12-Km, Sheikhupura Road, Lahore.
‘Substandard’ on the basis ofPhysical Description & Assay Testand ‘Adulterated’ as per section 3(a)(iv) of Drugs Act, 1976.
Injection Neocobal

Reg. No. 042601
Mecobalamine 0.5mg/mlS-2455M/s Pulse Pharmaceuticals (Pvt.) Ltd.,
Sua Aasil, Raiwind Road, Lahore.
‘Substandard’ on the basis ofAssay Testand ‘Adulterated’ as per Drugs Act, 1976.
Risk Statement:The use of substandard products can result in therapy failure, increasing the risk of complications, particularly in vulnerable groups such as immunocompromised individuals, as well as pediatric and geriatric population.
Action Initiated– The regulatory field force of DRAP and Provincial Drug Control departments has been directed to immediately conduct market surveys for detection and removal of these products from the market.
– All pharmacists and chemists working at distributors and pharmacies should immediately check their stocks and stop supplying these products. The remaining stocks should be quarantined, and the information of their supplier should be immediately provided to their area drug inspector to ensure the removal of falsified product.

Distributors and pharmacies are advised to be vigilant and report any suspected batch of the product(s) in the supply chain to the DRAP using the online form, or by Email at gsmsdra.gov.pk.

Regulatory field force of all federating units (DRAP, Provincial Health Departments, and States) has also increased the surveillance in the market to ensure the effective recall of defective product(s).
Advice for Healthcare ProfessionalsDRAP requests to enhance vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by this defective batch of the product.  

-Adverse reactions or quality problems experienced with this product may be reported to the National Pharmacovigilance Centre(NPC), DRAP using the
Adverse Event Reporting Form or online through this link.

-Please click here for further information on problem reporting to DRAP.
Advice for Consumers-Consumers should stop using these product bearing the affected batch number(s). They shall contact their physician or healthcare provider(s) if they have experienced any problem that may be related to using this product.

-All therapeutic products must be obtained from authorized licensed pharmacies /outlets. Their authenticity and condition should be carefully checked. If you have any doubts, please seek advice from your pharmacist.

Decisions of the Medical Device Board from 75-85th Meetings

The Medical Device Board (MDB) of the Drug Regulatory Authority of Pakistan, in its 75-85th meetings, has decided on the following applications for registration/enlistment of medical devices. The applicants, where applicable, are requested to furnish the requisite information/documentation as directed by the Medical Device Board. The details are provided in the below attachments.

Decisions of the 75th Meeting of the Medical Device Board

Decisions of the 76th Meeting of the Medical Device Board

Decisions of the 77th Meeting of the Medical Device Board

Decisions of the 79th Meeting of the Medical Device Board

Decisions of the 80th Meeting of the Medical Device Board

Decisions of the 81st Meeting of the Medical Device Board

Decisions of the 82nd Meeting of the Medical Device Board

Decisions of the 83rd Meeting of the Medical Device Board

Decisions of the 84th Meeting of the Medical Device Board

Apply for Membership of the Central Licensing Board, DRAP